APOE Haplotype Phasing Using ONT Long-Read Sequencing Reveals Two

Common ε3 and ε4 intragenic haplotypes in the Spanish Population

Pablo García-González[1,2,3*], Raquel Puerta[1,3*], Amanda Cano[1,2], Claudia Olivè[1], Marta Marquié[1,2],

Sergi Valero[1,2], Maitee Rosende-Roca[1,2], Montserrat Alegret[1,2], Pilar Sanz[1], Frederik Brosseron[4],

Pamela Martino-Adami[5], Itziar de Rojas[1,2,6], Michael Heneka[6], Alfredo Ramírez[5,7,8,9,10], Arcadi

Navarro[11,12,13,14], María Eugenia Sáez[1,15], Lluís Tárraga[1,2], José E. Cavazos[16,17], Mercè Boada[1,2],

María Victoria Fernandez[1], Alfredo Cabrera-Socorro[18*], Agustín Ruiz[1,2,17,19*,¥]

1. ACE Alzheimer Center Barcelona – Universitat Internacional de Catalunya, Barcelona,
Spain.

2. CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases,
National Institute of Health Carlos III, Madrid, Spain.

3. PhD program in Biotecnology, Faculty of Pharmacy and Food Sciences, University of
Barcelona, 08028- Barcelona, Spain.

4. Universitätsklinikum Bonn & Deutsches Zentrum für Neurodegenerative Erkrankungen
(DZNE) Bonn, Germany.

5. Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and
Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of
Cologne, 50937 Cologne, Germany

6. Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-
sur-Alzette/Belvaux, Luxembourg.

7. Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital
Bonn, Medical Faculty, 53127 Bonn, Germany.

8. German Center for Neurodegenerative Diseases (DZNE), 53127 Bonn, Germany.

9. Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD),
University of Cologne, 50931 Cologne, Germany.

10. Department of Psychiatry and Glenn, Biggs Institute for Alzheimer's and
Neurodegenerative Diseases, San Antonio, TX, USA.

11. Institució Catalana de Recerca i Estudis Avançats (ICREA) and Universitat Pompeu
Fabra. Pg. Lluís Companys 23, 08010, Barcelona, Spain

12. IBE, Institute of Evolutionary Biology (UPF-CSIC), Department of Medicine and Life
Sciences, Universitat Pompeu Fabra. PRBB, C. Doctor Aiguader N88, 08003 Barcelona,
Spain

13. Center for Genomic Regulation (CRG), The Barcelona Institute of Science and
Technology, Av. Doctor Aiguader, N88, 08003 Barcelona, Spain.

14. BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation, C. Wellington 30,
08005, Barcelona, Spain

15. CAEBI, Centro Andaluz de Estudios Bioinformáticos, Sevilla, Spain.

16. South Texas Medical Science Training Program, University of Texas Health San
Antonio, San Antonio, TX, USA.

17. Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX,
USA.

18. Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium.

19. Department of Microbiology, Immunology and Molecular Genetics. Long School of
Medicine. University of Texas Health Science Center, San Antonio, TX, USA.

*These authors contributed equally to this work

¥Correspondence to:

Prof. Agustin Ruiz MD PhD.

Research Center & Memory Clinic. ACE Alzheimer Center Barcelona. Marques de
Sentmenat 57. 08028-Barcelona. Spain. aruiz@fundacioace.org

Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases. University of Texas
Health Science Center, 78229 Floyd Curl Dr. San Antonio, TX, USA. ruiza5@uthscsa.edu

Keywords: APOE, Alzheimer, epsilon 4 allele, haplotype, phasing, Oxford Nanopore, NGS, long-

read sequencing, MCI, dementia, gene

Abstract

Background: The apolipoprotein E (*APOE*) gene is a key genetic determinant of Alzheimer's

disease (AD) risk, with the ε4 allele significantly increasing susceptibility. While the pathogenic

effects of the ε4 allele are well established, the functional impact of distinct haplotype

configurations within the broader ε3 and ε4 backgrounds remains poorly understood. This study

investigates the role of intragenic sub haplotypes in modulating *APOE* expression and their

potential influence on AD progression.

Methods: We utilized Oxford Nanopore Technology (ONT) long-read sequencing to phase

variants within a 4-kilobase comprising the *APOE* locus in a cohort of 1,265 individuals with

known *APOE* genotypes. We evaluated the impact of the identified intragenic haplotypes on

APOE protein levels in cerebrospinal fluid (CSF) using the Olink platform, adjusting for

demographic and molecular covariates. Statistical modeling was employed to assess the

independent effects of these haplotypes alongside traditional *APOE* genotypes. Additionally, their

influence on dementia progression in mild cognitive impairment (MCI) subjects was analyzed

using adjusted Cox proportional hazards models.

Results: Our analysis identified 48 Single Nucleotide Variants (SNVs) within a 4-kilobase region

containing the *APOE* gene, including nine novel variants. Phasing of variants within the *APOE*

locus revealed 59 unique haplotypes in the Spanish population, which were grouped into five

major haplogroups—ε2, ε3A, ε3B, ε4A, and ε4B—including two common haplogroups for each

of the ε3 and ε4 isoforms. The ε4A haplogroup was associated with a significant decrease in

APOE ε4 protein levels in CSF (p = 0.004), suggesting a regulatory mechanism that may mitigate

the toxic gain-of-function effect typically attributed to the ε4 allele. Conversely, the ε3B

haplogroup was linked to increased APOE ε3 protein levels in ε3/ε4 carriers (p = 0.025),

potentially serving a compensatory role.

These effects were independent of overall *APOE* genotype and remained significant after

adjusting for covariates. Both haplogroups (ε4A and ε3B) demonstrated protective effects in the

progression from MCI to dementia, underscoring their potential relevance in Alzheimer's disease.

Conclusions: This study provides new insights into the intragenic allelic variability of the *APOE*

gene, demonstrating that intragenic *APOE* haplogroups within the ε3 and ε4 backgrounds can

modulate *APOE* isoform expression in ways that might modulate AD. Our findings highlight the

importance of considering haplotype-specific effects when interpreting the functional impact of

APOE and in designing targeted therapeutic strategies. Further research is needed to explore the

broader regulatory network of the *APOE* locus and its interaction with neighboring loci in the

19q13 region.

Keywords: Alzheimer, *APOE*, haplotype, long-read sequencing, risk, progression, protein levels

1. Introduction

Alzheimer's disease (AD) and related dementias present a growing global health challenge as

populations age, with significant social and economic burdens[1,2]. AD, the most common cause of

dementia, is characterized by a progressive decline in cognitive function, leading to memory

impairment, loss of independence, and ultimately, death. The profound effects on patients and

caregivers, coupled with the strain on healthcare systems, highlight the urgent need for effective

strategies to prevent and manage this disease[3]. Genetic factors are critical in developing late-onset

AD (LOAD), with the Apolipoprotein E (*APOE*) gene identified as a key contributor.

Specifically, the *APOE* ε4 allele significantly increases the risk for AD, while the ε2 allele appears

to have a protective effect[4,5]. However, the risk associated with the *APOE* ε4 allele varies across

populations[6–11]. Notably, individuals of African ancestry exhibit a reduced risk of Alzheimer's

disease (AD) associated with the ε4 allele compared to those of European descent, suggesting the

presence of protective effects within specific genetic backgrounds[12] . Recent studies have

highlighted a significant interaction between *APOE* ε4 and the rs10423769-A allele, which

reduces AD risk by up to 75% in African-origin haplotypes[12]. Understanding the genetic

mechanisms modulating *APOE* and its association with AD—particularly the role of cis and trans

regulatory elements—remains critical for developing targeted interventions aimed at mitigating

the impact of this major risk factor and ultimately reducing the societal burden of the disease.

The *APOE* gene encodes a major regulator of lipid metabolism, functioning by binding and

transporting lipids within the bloodstream and the brain. In neurodegenerative diseases, *APOE*

lipoprotein plays pivotal roles in amyloid-β clearance, synaptic maintenance, and

neuroinflammatory processes[13,14]. The *APOE* ε4 isoform has been shown to impair amyloid-β

clearance, promoting its accumulation in the brain, a hallmark of AD pathology[15]. Furthermore,

the ε4 isoform is associated with enhanced neuroinflammation[16] and oxidative stress[17],

contributing to neuronal damage and accelerating disease progression. These distinct roles of

APOE isoforms emphasize the importance of understanding their functional differences,

particularly in the context of AD pathology and progression[18].

Oxford Nanopore Technology (ONT)[19] offers a cutting-edge solution for overcoming challenges

associated with genetic analysis, particularly the issue of homoplasy, where genetic variants may

independently arise but appear identical[20]. Homoplasy is a well-known issue within the *APOE*

locus, complicating efforts to link genetic variants with disease phenotypes[21]. ONT's long-read

sequencing technology provides the ability to phase DNA variations, enabling the precise

connection of single nucleotide variants (SNVs) with haplotypes and regulatory elements that

modulate *APOE* gene expression. This level of resolution facilitates a clearer distinction between

benign and disease-associated variants, enhancing our understanding of how different *APOE*

haplotypes influence disease risk and progression across diverse populations[22]. The ability to

phase the classic *APOE* isoforms with other variants located in functional elements provides an

invaluable tool for elucidating the mechanisms by which cis-genetic variants configure *APOE*

sub-haplotypes. This understanding extends beyond the classical ε2/ε3/ε4 isoforms, shedding

light on how specific combinations contribute to Alzheimer's disease and other neurodegenerative

conditions

In this study, we explore the association between intragenic *APOE* haplotypes and Alzheimer's

disease (AD) progression, with a special focus on identifying existing haplotypes within the ε3

and ε4 protein isoforms. Utilizing ONT-based long-read sequencing, we analyzed the distribution

of intragenic *APOE* sub-haplotypes in a large Spanish cohort, identifying 48 SNVs, including

both known and novel variants. Our analysis specifically focuses on examining common variants

within regulatory motifs that influence CSF APOE levels and AD biomarkers in an isoform-

specific manner. Moreover, we identified distinct ε3 and ε4 sub-haplotypes that appear to

influence the rate of conversion from mild cognitive impairment (MCI) to dementia, providing

potential genetic markers for individualized disease risk assessment and therapeutic intervention.

2. Materials and methods

2.a. The ACE Alzheimer's Center Barcelona CSF cohort (ACE)

Patient recruitment and evaluation were conducted at the Memory Disorders Unit of the ACE

Alzheimer Center Barcelona (ACE) in Spain, spanning the years 2016 to 2021[23]. Diagnoses were

established through consensus discussions involving neurologists, neuropsychologists, and social

workers during case conferences. All patients classified as having mild cognitive impairment

(MCI) met the criteria outlined by *Petersen et al.* for MCI diagnosis[24,25]. These criteria include

subjective memory complaints, a noticeable decline from normal cognitive function, intact daily

living activities, the absence of dementia, and measurable impairments in one or more cognitive

domains, whether amnestic MCI (single or multiple domains). Impairment thresholds were

determined according to age and education level. Specific cutoffs for the tests in the

neuropsychological battery (NBACE) are detailed in prior publications[26], with individuals scoring

below these thresholds classified as having MCI.

For patients with MCI who were later followed up, dementia diagnoses were made according to

the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria[27].

Dementia subtypes were further categorized based on the 2011 National Institute on Aging-

Alzheimer's Association (NIA-AA) criteria for Alzheimer's disease[28], the NINDS-AIREN criteria

for vascular dementia[29], frontotemporal dementia[30], and the diagnostic criteria for Lewy body

dementia[31].

Fasting patients provided paired CSF and plasma samples using standardized clinical methods.

CSF was collected via lumbar puncture from the L3-L4 intervertebral space following standard

protocols[32]. The procedure, performed by skilled neurologists under local anesthesia (1%

mepivacaine), involved the patient sitting upright. Two 10-ml polypropylene tubes (Sarstedt ref

62,610,018) of CSF were collected, with one tube used for routine biochemistry tests (glucose,

total protein, proteinogram, cell type, and count). The second tube was centrifuged (2000xg, 10

min at 4°C), aliquoted into polypropylene tubes (Sarstedt ref 72,694,007), and stored at -80°C

within two hours of collection. On the day of biomarker analysis, an aliquot was thawed at room

temperature, vortexed for 5–10 seconds, and analyzed for Aβ1-42, total tau (t-tau), and

phosphorylated tau (p-tau) levels using enzyme-linked immunosorbent assays (ELISAs): Innotest

Aβ1-42, Innotest hTAU Ag, and Innotest PHOSPHO-TAU (181P) (Fujirebio Europe)[32–34].

CSF protein levels of APOE were measured using conventional ELISA protocols as previously

described[35]. In addition, APOE protein levels, along with the protein products of loci near the

APOE gene (NECTIN2, BCAM, and APOC2), were also obtained from OLINK panels generated

in our prior work as part of the PREADAPT JPND programs[36]. Each selected protein's

measurements were adjusted for age, sex, and the principal components of the CSF proteome

variance. Standardized residuals were then used as dependent variables in subsequent analyses

(see below).

Informed consents for lumbar puncture, genetic analyses, and the anonymized use of clinical

records for research were approved by the Ethics Committee of the Hospital Clinic i Provincial

de Barcelona (Barcelona, Spain) in accordance with Spanish biomedical laws (Law 14/2007, of

July 3, on biomedical research; Royal Decree 1716/2011, of November 18). The study also

adhered to the recommendations of the Declaration of Helsinki. The Harpone project,

encompassing all the research described in this manuscript, has also been approved by the Ethics

Committee of the Hospital de Bellvitge (Barcelona, Spain) (Acta 04/21).

2.b. DNA extraction and *APOE* genotyping

DNA extraction from blood specimens was performed automatically using standard procedures with the DNA Chemagic system (Perkin Elmer) or the Maxwell RSC48 instrument (Promega). Extensive DNA quality control was conducted, and only samples with DNA concentrations greater than 10 ng/µl and high integrity were included for *APOE* genotyping. The isoforms were determined by TaqMan probe analysis in the Real-Time PCR QuantStudio3 (ThermoFisher, Waltham, Massachusetts, USA) system or extracted from Affymetrix Axiom SP biobank arrays processed as previously described [37–39].

2.c. Long PCR amplification of the *APOE* locus

Long-range PCR was performed to amplify the *APOE* locus using primer pairs designed with the National Institutes of Health (NIH) primer designing tool software (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) to cover the entire region, from the promoter to the 3' UTR. We used Roche's Expand™ Long Template PCR System kit (UNSPSC number: 41106300) for PCR amplification. To find the optimal reaction conditions, we tested in a single sample three different primer pairs, along with different DMSO concentrations (2.5, 5.0, 7.5 and 10%) and three kit-supplied reaction buffers (Supp. Table 1, Supp. Fig. 1). Based on our results, we used a 10% concentration of DMSO, kit-supplied reaction buffer 2 and the primer pair labeled "APOE_III" for optimal long-range amplification of the region. The selected primers were: forward primer 5'- ACAGGGTCAGGAAAGGAGGA -3' and reverse primer 5'- GGCTGGGGCTTAGAGGAAAT -3', spanning a 3939 bp fragment surrounding the *APOE* locus. The reaction mixture included a high-fidelity DNA polymerase, PCR dNTP mix (Roche, UNSPSC code 41106300), template DNA, primers, DMSO, and buffer (including 17.5 mM $MgCl_2$) (Supp. Table 2). The PCR was carried out on a Thermo Fisher QuantStudio 3 Real-Time Thermal Cycler with the following conditions: initial denaturation at 94°C for 2 minutes, followed by 40 cycles of denaturation at 92°C for 10 seconds, annealing at 59°C for 30 seconds, and extension at 68°C for 4 minutes. A ramp increasing the elongation time by 20 seconds per cycle starting in cycle 11, and a final 10-minute elongation step at 68ºC were included in the protocol

to ensure complete amplification of the DNA segment. Following amplification, PCR products

were purified using AMpure XP beads (Beckman Coulter, A63881), following the manufacturer's

protocol to remove salts, primers, nucleotides, and enzymes, ensuring high-quality DNA for

downstream applications. Amplification success was verified via automated capillary

electrophoresis using the LabChip GX Touch Nucleic Acid Analyzer (Revvity, CLS138162) and

the DNA 12K Reagent Kit (Revvity, 760569).

2.d. ONT long-read Sequencing and Library Preparation

For the ONT sequencing of the *APOE* amplicon, we employed the ONT 96 Native Barcoding Kit

(EXP-NBD196) to multiplex 96 samples in a single reaction, and the ONT Ligation Sequencing

Kit (SQK-LSK109). We followed the protocol recommended by ONT based on these reagent

kits: "Amplicon barcoding with Native Barcoding Expansion 96 (EXP-NBD196, and SQK-

LSK109), Version: NBA_9102_v109_revA_09Jul2020". Purified *APOE* amplicons (100 fmoles)

were quantified using the Quant-iT™ PicoGreen™ dsDNA Assay Kits (Invitrogen, P7589), and

250 ng were taken forward for barcode ligation. This process involved two steps: first, the ends

of the DNA fragments were repaired using the NEBNext® Ultra™ II End Repair/dA-Tailing

Module (New England Biolabs, E7546), following manufacturer instructions. This reaction is

optimized for the subsequent ligation reaction, yielding 5' phosphorylated and 3' dA-tailed ends.

Then, unique barcodes were ligated to each sample using the NEB Blunt/TA Ligase Master Mix

module (New England Biolabs, M0367). Subsequently, the barcoded library was pooled together

and 480 uL were carried forward for purification using Ampure XP beads, removing excess

barcodes and small fragments, and collected in a volume of 30 uL. Absorbance at 260 nm,

A260/A280 and A260/230 ratios, measured with a BioTek Epoch Microplate Spectrophotometer,

were used subsequently for rapid estimation of DNA concentration and purity. 500 ng (200 fmol)

of the pulled library was then ligated to ONT sequencing adapters using the NEBNext Quick

Ligation Module (New England Biolabs, E6056), following manufacturer instructions. A final

AMpure XP purification step was performed to remove unwanted products. Finally, 100 ng (~40

fmoles) of the library were loaded onto primed ONT R9.4.1 flow cells. Sequencing was carried

out on a MinION platform, enabling real-time demultiplexing by Guppy, until satisfactory

coverage of all barcoded samples was achieved (at least 100x coverage of the least represented

barcodes).

2.e. Bioinformatics Analysis

The dry lab workflow for the identification of missense mutations in the *APOE* locus using Oxford

Nanopore Technologies (ONT) sequencing data is based on the protocol described by *Leija-*

Salazar et al.[40]. This bioinformatics processing involves a series of computational steps, starting

from raw signal data and culminating in the generation of a multi-sample VCF file. The process

begins with basecalling and demultiplexing using Guppy v4.5.2

(https://nanoporetech.com/software/other/guppy), which converts raw electrical signals from the

nanopore sequencing (.fast5) into nucleotide sequences (.fastq files), while simultaneously

assigning each read to its corresponding barcode. Basecalling was conducted using the

dna_r9.4.1_450bps_hac.cfg --config file for high accuracy. We generated in-silico gel

electrophoresis images to visually assess the read length of sequencing reads, ensuring the signal

detected for each barcode was present in the expected length (3939bp). Following this, the quality

of the reads is assessed; only those marked as "PASS" and within the length range of 3800 to

4000 base pairs were retained to ensure only full-length *APOE* amplicons were included in

downstream analysis. Subsequently, nanopolish (https://github.com/jts/nanopolish) was utilized

to index the .fastq files, linking the sequencing data back to the original raw signal data in the

.fast5 files. This linkage is crucial for the later implementation of signal-based error correction

during variant calling. We used two different aligners—Graphmap v0.5.2 and NGLMR v0.2.7—

to generate the SAM files providing the positional information of the filtered and indexed reads

within the reference genome (GRCh38.p13). Subsequently, we used samtools v1.10

(http://www.htslib.org/) to convert the files to BAM format, and then sort and index the files.

nanopolish was subsequently used for variant calling, employing the raw nanopore signal to

enhance the accuracy of mutation detection. The output of this step is a .vcf file containing the

identified variants within the *APOE* locus for each sample. Individual .vcf files from each sample

were then merged using bcftools 1.9 (https://samtools.github.io/bcftools), and sample IDs were

reassigned based on barcode correspondence, resulting in a multi-sample .vcf file that

consolidates the variant information across all 96 samples. SNP identifiers and TOPMed allele

frequencies were annotated based on dbSNP build 151 (GRCh38.p7). The mean ratio of the

QUAL and TotalReads parameters generated by nanopolish was used as a quality measure for

variant calling. Overall, this comprehensive approach allowed for the accurate detection of

missense mutations in the *APOE* locus by leveraging both basecalled sequences and the inherent

error-correction capabilities of Nanopolish based on the raw nanopore sequencing data.

2.f. Variant phasing and further haplotype analyses

The   phasing   of   *APOE*   haplotypes   was   conducted   using   WhatsHap

(https://whatshap.readthedocs.io), a tool designed for accurate read-based phasing of long-read

sequencing data[41,42]. WhatsHap performs phasing by directly utilizing DNA sequencing reads, a

method known as read-based phasing or haplotype assembly, which is particularly suited for long

reads but also works well with short reads. By leveraging the long-range information from ONT

sequencing, WhatsHap effectively separated detected variants into their respective haplotypes,

enabling the reconstruction of complete *APOE* haplotypes for each individual. To facilitate

downstream analyses, we developed a custom code. This program automated the extraction of

individual-level haplotypes from the phased VCFs generated by WhatsHap, calculated haplotype

frequencies, and encoded individual-level subhaplotypes for subsequent use. Additionally, the

code prepared nexus files for evolutionary analyses in MEGA and formatted data for phenotype-

haplotype correlation studies in SPSS.

Following the phasing process, the evolutionary relationships of the *APOE* haplotypes were

examined using MEGA Software v11.0.13 (https://www.megasoftware.net)[43]. MEGA was used

for the alignment and comparison of haplotype sequences, enabling the construction of

phylogenetic trees and the assessment of evolutionary divergence. Specifically, the evolutionary

history was inferred using the Maximum Likelihood method with the Tamura-Nei model[44]. The

tree was drawn to scale, with branch lengths representing the number of substitutions per site.

Sub-haplotypes derived from the different *APOE* common haplotypes were color-coded to

facilitate interpretation: green for ε2, orange for ε3, red for ε4, and blue for the ancestral sequence

extracted from Ensembl[45].

2.g. Statistical analysis

For statistical analysis, SPSS (version 26.0 for Windows, IBM, Armonk, New York, USA) was

used. Group differences were assessed using the Chi-Square test for categorical variables and the

t-test for quantitative variables. To evaluate the impact of *APOE* sub haplotypes on the risk of

conversion to dementia, Kaplan–Meier curves were generated, stratifying mild cognitive

impairment (MCI) subjects into sub-haplotype categories based on the presence of ε3 or ε4

variants, encoded as the presence/absence of potentially disease-modifying subhaplotypes. Cox

proportional-hazard regressions were then conducted to identify potential confounders of the

categories, adjusting for covariates including age at lumbar puncture, sex, baseline MMSE score,

formal education (years), AD biomarker levels, and biomarker determination methods (ELISA or

CLEIA). To examine the impact of subhaplotypes on CSF AD biomarkers or CSF protein levels

of APOE, BCAM, APOC3, and NECTIN2, a general linear model of the standardized residuals

of the target proteins was further adjusted for AD biomarkers (except when exploring the impact

of *APOE* subhaplotypes on AD biomarkers), *APOE* isoforms (ε2/ε3/ε4), age, sex, and the

principal components of the proteome variance as previously reported[46]. The significance level

was set at α = 0.05.

3. Results

3.a. ACE CSF cohort description

Table 1 provides a detailed descriptive overview of the demographic, clinical, neurological, and

biological characteristics of the ACE CSF cohort, comprising 1,267 subjects sequenced for the

APOE gene using ONT long-read sequencing. The ACE cohort is predominantly female (57.9%),

with a mean age of 72.68 years (SD = 8.46), a mean body mass index (BMI) of 26.9 kg/m² (SD

= 4.36), and an average of 8.17 years of education (SD = 4.77). Syndromic diagnoses based on

Clinical Dementia Rating (CDR) scores include 6.2% with subjective cognitive decline (SCD,

CDR = 0), 62.7% with mild cognitive impairment (MCI, CDR = 0.5), and 30.1% with dementia

(CDR > 0). The AT(N) classification reveals that 33% of participants fall under the A+T+N+

category, indicating the presence of both amyloid pathology and tauopathy, while 29.7% are A-

T-N-, showing no evidence of AD pathology. Of note, a relatively large proportion of individuals

(37.7%) displayed intermediate AT(N) profiles, with or without the presence of amyloidosis,

suggesting the existence of a relatively big proportion of individuals with an ongoing

neurodegenerative process that does not yet fulfill the full positive AT(N) molecular pattern

(Table 1). Additional clinical and biochemical data include a mean Mini-Mental State

Examination (MMSE) score of 24.4 (SD = 4.41), and CSF biomarkers with mean concentrations

of 72.28 pg/mL (SD = 45.35) for phosphorylated tau (pTau181), 811.2 pg/mL (SD = 393.5) for

amyloid β42, and 469.2 pg/mL (SD = 330.1) for total tau. Lastly, among the MCI group with

follow-up information available (n=720), 49.1% converted to dementia, reflecting the

longitudinal progression of a significant proportion of MCI subjects. Analysis of *APOE* genotype

distribution shows that, as expected, the ε3/ε3 genotype is the most prevalent (57.9%), followed

by ε3/ε4 (27.9%), with less frequent occurrences of ε2/ε3 (7.2%), ε4/ε4 (4.7%), ε2/ε4 (1.9%), and

ε2/ε2 (0.3%).

3.b. DNA Sequencing of the *APOE* locus in the Spanish Population

We applied Oxford Nanopore Technologies (ONT) long-read DNA sequencing to a 3939 bp

region surrounding the *APOE* locus (from the promoter to the 3'UTR) in our cohort of 1,267

individuals (Table 1). Our study focuses exclusively on SNVs within the *APOE* region on

chromosome 19 due to the known limitations of ONT sequencing, which tends to be less reliable

for detecting insertion and deletion (indel) mutations[47]. By limiting our analysis to SNVs, we

leverage the strengths of ONT sequencing, ensuring higher confidence in variant detection and

reducing the risk of false positives typically associated with indel identification. The results of

this sequencing project are presented in Table 2 and Fig. 1. Overall, we identified 48 single

nucleotide variants (SNVs) in the *APOE* gene region using the methods and criteria applied.

We categorized detected SNVs based on their frequency and novelty status: 8 were common

(MAF>0.01), 7 rare (0.01>MAF>0.001), 24 very rare (MAF<0.001), and 9 unlisted in dbSNP.

These classifications are derived using allele frequency data from the TOPMed[48] and GR@ACE

[37–39] populations. The eight common variants are well-documented in population databases,

indicating a relatively high frequency in the general population. Notably, the observed and

expected frequencies of SNVs with a frequency of 1% or higher in previous studies align almost

perfectly with the frequencies observed in our study, underscoring the reliability of the results for

SNVs using the ONT technology implemented (Fig. 2). These variants are primarily distributed

in intronic and exonic regions, suggesting potential regulatory or coding impacts.

The 7 rare variants are less prevalent, and their occurrence is limited to specific subpopulations

or contexts. The 24 very rare variants exhibit an extremely low frequency (<0.1%) in global

databases and are mostly singletons, underscoring their possible relevance to niche population

studies or for tracking rare genetic traits. We also generated confidence ratings for each variant

based on their frequency and sequencing quality, with 37 variants labeled as Very Good or Good,

and all the new ones marked with caution (Fig. 1, Supp. Table 3). We labeled two additional

variants as 'caution': rs1488164590 was detected in a single chromosome, had an exceptionally

low QUAL to TotalReads ratio, and was present in a homopolymer region; rs147236548 was

called in only one chromosome using the Graphmap but not the NGLMR aligner. Comparing our

data with available TOPMed imputed genotypes from the GR@ACE project [37–39], we confirmed

that the Graphmap call matched the genotype of this sample, so we kept this aligner over NGLMR

for downstream analyses. This emphasizes the robustness of the ONT sequencing approach while

highlighting new variants requiring careful interpretation. Additionally, substitution types

indicate that 31 are transitions and 17 are transversions (Ts/Tv rate 1.82). We also found 9 novel

variants are not found in public databases, suggesting they are unique to this dataset and could

represent newly identified mutations. Of these, 6 are located within intronic regions, 1 is in the

5'UTR region, and 2 are found in exon 4 (Table 2).

We analyzed these 9 potentially novel SNVs using the Ensembl Variant effect prediction tool

(VEP)[49], revealing that the majority are classified as having a modifier impact. This classification

typically means that these variants do not directly alter the protein function but may influence

gene regulation, splicing, or transcriptional control (Supp. Table 4). Most of these variants are in

upstream, downstream, or intronic regions of the *APOE* gene, suggesting that their impact is more

likely to be on gene expression rather than protein coding. Two new variants, specifically

19:44908665:C/T and 19:44908797:C/A, were identified as synonymous variants in the exon 4

of *APOE* but do not affect the resulting amino acid. These types of changes often have minimal

impact on protein structure, although they could potentially affect splicing or regulatory elements.

VEP confirmed that analyzed variants appear are novel, as they were not registered in the VEP

databases (Supp. Table 4). We repeated the VEP analysis using the 15 coding SNVs detected in

this study (Supp. Table 5). The most important VEP predictions for coding variants identified in

the *APOE* locus are summarized in Fig. 3. Half of the observed variants are classified as Disease

Causing (Predicted+Literature), indicating potential pathogenicity based on in silico predictions.

This visualization helps in identifying the functional impact of each variant based on CADD

scores, providing further insights into the severity and potential functional consequences of the

observed genetic alterations. Only the *APOE* variants encoding the classic *APOE* alleles

(rs429358 tagging ε4, and rs7412 tagging ε2), rs563571689 (D19N substitution) and rs121918393

(R180H substitution also known as Christchurch mutation) displayed relatively high CADD

scores although with a modest impact according to standard CADD criteria even not reaching a

moderately deleterious score (scoring ranged between 5 and 10)[50].

3.c. Haplotype analysis of the *APOE* locus using ONT long read sequences

In this section, we present a comprehensive analysis of the *APOE* haplotypes derived from the

SNVs in the Spanish population. Specifically, we are focusing on characterizing intragenic 4KB-

haplotypes derived from a detailed examination of the phase of the 48 detected variants. This

analysis was run using WhatsHap[41], known for its high accuracy in phasing genomic variants

through sequencing data.

We identified 59 distinct *APOE* haplotypes in the Spanish population, ranging from a maximum

of 970 (38.07%) observations for the most common haplotype (Haplotype 1) to just a single

observation (0.04% of the total observations) for the rarest haplotypes (Supp. Table 6). This count

reflects the prevalence of each haplotype within the population, offering insights into its genetic

structure in the *APOE* locus. We also categorized the haplotypes into haplogroups, considering

the common *APOE* isoform backgrounds (ε2, ε3, ε4) and the presence or absence of the

alternative sequence (T-allele) of the homoplasic SNV rs405509 (Supp. Fig. 2). For instance,

Haplotype 1 is classified under haplogroup 3a, while Haplotype 3 falls under haplogroup 4a. This

classification framework aids in understanding the evolutionary relationships and potential health

implications associated with each haplotype.

A detailed examination of haplotype frequencies revealed a total of 17 distinct haplotypes that

exhibited three or more occurrences among the sampled individuals (Fig. 4, Table 3). Our

findings revealed that the five most prevalent haplotypes accounted for 92.74% of all haplotypes

identified in this cohort. Specifically, Haplotype 1 and Haplotype 2 are associated with the ε3

allele, while Haplotype 3 and Haplotype 4 are linked to the ε4 allele. Additionally, we identified

a common ε2 haplotype, designated as Haplotype 5. The predominance of these haplotypes

suggests shared ancestry within this population, offering valuable insights into the genetic

landscape of the *APOE* gene and its potential health implications. This haplotype frequency

distribution underscores the genetic diversity present within the population, which may be

influenced by historical demographic factors including migration, genetic drift, and natural

selection. The high frequency of certain haplotypes suggests a possible selective advantage, which

could be related to environmental adaptations or other health-related traits. This aspect of our

findings provides a foundational understanding of the *APOE* intragenic variation that exists within

the Spanish population, reflecting broader evolutionary processes.

Importantly, this study firmly demonstrates the existence of two common haplotypes for ε3 and

ε4, just determined by the phasing of a single homoplasic variant located in the promoter region

of the *APOE* gene (rs405509). We utilized this information to simplify and statistically manage a

panoply of the less common haplotypes, which were categorized into A or B haplogroups based

on the correct phasing of classic *APOE* isoforms and the presence of the T-allele of the rs405509

variants (Fig. 4, Supp. Table 6).

To elucidate the evolutionary relationships among the identified haplotypes, we employed the

Maximum Likelihood method in conjunction with the Tamura-Nei model implemented in the

MEGA software[43] (Fig. 5). These are well-established techniques in phylogenetic analysis. The

dataset for this analysis comprised a total of 60 alleles, including the 59 observed haplotypes

(Supp. Table 5) and the homo sapiens ancestral *APOE* allele obtained from Ensembl[45]. This

analysis yielded a phylogenetic tree with a log likelihood of -404.80, indicating robust statistical

support for the inferred relationships among haplotypes. The constructed tree was scaled to

represent genetic distances, with branch lengths proportional to the number of nucleotide

substitutions per site. This visualization allowed for a clear interpretation of the evolutionary

trajectories and relationships among the haplotypes, revealing insights into how these genetic

variants may have diverged and adapted over time within the population (Fig. 5). According to

the MEGA analysis the oldest haplotype observed in the Spanish population is Haplotype 4,

corresponding to the 4b haplogroup of the *APOE* ε4 allele (Table 3). This information is fully

concordant with previous small-scale studies in other populations[21]. Furthermore, the analysis

permitted the identification of the exact haplotype context (Haplotype 26) of other missense

variants of the *APOE* coding sequence, including the *APOE* Christchurch mutation[51–53], which

occurs in the *APOE* ε3 isoform and haplogroup ε3b in the Spanish population (Supp. Table 6).

An intriguing aspect of our findings was the absence of a full ancestral sequence among the

Spanish *APOE* haplotypes examined. Instead, our analysis indicated that all haplotypes, except

for two singletons, harbored alternative sequences shared to Neanderthal-derived sequences at

two specific positions within the gene (rs1212454788 and rs749102800). This observation raises

the possibility of introgression, suggesting that some of the genetic material associated with the

APOE sequences in modern humans may have originated from interbreeding events between early

humans and Neanderthals. However, extended sequencing is needed to elucidate this possibility.

Furthermore, our analysis confirmed the presence of homoplasy for the variant rs405509, a

phenomenon previously documented[21]. This phenomenon complicates the phasing of *APOE*

haplotypes and introduces potential inconsistencies in understanding the relationships between

these genetic variants located in *APOE* regulatory regions and their associated phenotypic

outcomes. Homoplasy, defined as the independent occurrence of the same genetic variant in

distinct lineages, can obscure the accurate tracing of inheritance patterns and complicate

interpretations of their functional implications. As illustrated in the simplified Supp. Fig. 2, the

homoplasy observed for rs405509 could be attributed to a single ancestral recombination (or gene

conversion) event within the *APOE* gene. This event likely reshuffled SNVs in the promoters and

intronic enhancers of the *APOE* gene in the ancestral ε4b and possibly ε3b backgrounds, leading

to the differentiation of the ε3 and ε4 isoforms into the two (A and B) haplogroups in a single

mutation step. Subsequently, further diversification of haplotypes occurred within each observed

haplogroup, resulting in variants that differ by only 1-3 positions from the most common

haplotypes (Haplotypes 1-5). Supp. Fig. 2 displays a simplified phylogenetic network and the

corresponding genomic context of most common *APOE* intragenic haplotypes observed in the

Spanish population, highlighting their evolutionary relationships and associated regulatory

elements within the *APOE* locus and the classic protein isoforms.

3.d. Exploring *APOE* haplogroups effects in Alzheimer's Disease

As previously mentioned, our technique permitted us to separate ε3 and ε4 isoforms into two

haplogroups. We decided to investigate the potential impact of these common haplogroups on

Alzheimer's disease progression and other potentially relevant endophenotypes. We initially split

our population by *APOE* haplogroups and detected the expected 15 categories resulting from the

combination of the five common haplogroups (ε2, ε3a, ε3b, ε4a and ε4b). Supp. Fig. 3 illustrates

the distribution and survival analysis of *APOE* haplogenotypes stratified by these *APOE*

haplogroups. Panel A shows the frequency distribution of these haplogenotypes, revealing that

`3a/3b`, `3a/3a`, and `3b/3b` are the most common. Panel B presents survival curves for all 15

haplogenotypes, indicating distinct survival patterns for each group. Panels C-E display specific

APOE genotypes analyses: ε3/ε3 carriers (Panel C), ε3/ε4 carriers (Panel D), and ε4/ε4 carriers

(Panel E) further divided by relevant epsilon haplogroups (`3a/3a`, `3a/3b`, `3b/3b` for ε3

haplogroups and `4a/4a`, `4a/4b`, `4b/4b` for ε4 haplogroups), revealing varying disease

progression probabilities among these categories. The generation of haplogroups enhances

analytical power by refining the categorization of subjects. However, the excess of categories

observed tends to reduce statistical power. Despite of this limitation, our initial exploration

revealed a significant impact of the haplogroups in the global analysis (panel B) and for the 3b

haplogroup in ε3/ε3 carriers ($p < 0.04$), along with a trend toward association for the 4A

haplogroup (Supp. Fig. 3).

Overall, we observed evidence suggesting protective effects of the 4A and 3B haplogroups.

Consequently, we encoded two dichotomous variables— "presence of 4A" and "presence of 3B"

haplogroups—to further investigate their potential effects in detail and to assess the impact of

other important covariates that might confound our observations in MCI to AD Disease

conversion. Following this idea, we conducted an analysis on the impact of haplogroups on MCI

to AD phenoconversion adjusted by demographics, AD biomarkers and the *APOE* genotype. Fig.

7 illustrates the results obtained for these analyses. Panel A shows the distribution of *APOE*

haplogroups in the cohort, categorized into four distinct groups: presence of the 4A haplogroup,

presence of the 3B haplogroup, presence of both protective haplogroups (3B/4A), and absence of

both (None).

Panel B depicts the results of the Cox proportional hazard risk model to explore 4A and 3B

haplogroups effect in MCI to AD phenotypic conversion, the table is showing the hazard ratios

(HR) of 4A and 3B haplogroups, adjusted for the *APOE* genotype, demographics, and AD

biomarkers. Both haplogroups demonstrated significant and independent protective effects in this

comprehensive analysis even in a model adjusted by the other haplogroup and the *APOE*

genotype. Panel C shows the survival curves specific effect of the 4A haplogroup, where carriers

had a significantly reduced risk of disease progression ($HR = 0.599$, $p = 0.002$). In the same way,

Panel D displays the effect of the 3B haplogroup, highlighting its protective association ($HR =$

0.79, p = 0.037). These results suggest that both haplogroups confer independent protective

effects and that encoding dichotomous variables based on these haplogroups might be

instrumental for understanding their contributions in modulating disease progression, beyond the

APOE genotype alone.

To gain insight into the potential mechanism of action of the haplogroups and considering that

sequence differences between them are located in the promoter region of the gene and other

intronic enhancers (Supp. Fig. 2), we hypothesized that the specific combination of these variants

with the ε3 and ε4 *APOE* isoforms might influence the expression levels of each isoform in the

central nervous system.

However, one critical issue for testing this hypothesis is ensuring the accuracy of protein level

measurements in the CSF. We reviewed results from various methods tested in our laboratory,

including SomaScan[54], ELISA measures previously reported by us[35], and the Olink platform[36].

Our exploratory study concluded that the Olink method provides the most reliable measurements,

as it explains a much larger proportion of variance in APOE protein levels when considering well-

known demographic and molecular factors, compared to other techniques (Fig. 7). Furthermore,

this method was also able to replicate the classic observation of decreasing APOE protein levels

by genotype (ε2 > ε3 > ε4), as reported by other research groups[55] (Fig. 7).

Thus, we decided to test our hypothesis using the Olink measurements of APOE lipoprotein in

CSF, which were available for 499 individuals with known *APOE* haplogroups (Fig. 7C and D).

To this end, we performed a general linear model using standardized residuals of Olink APOE

protein levels (adjusted for age, sex, principal components of the variance in the CSF proteome,

and AD biomarkers) as the dependent variable, with *APOE* genotype and the presence of the E4A

and E3B haplogroups as independent variables.

As expected, our results showed a strong effect of the *APOE* genotype on CSF APOE protein

levels (p = 2.1E-33, Fig. 7). Moreover, the model identified independent, though more modest,

effects of the protective haplogroups on APOE protein levels (Fig. 7). Interestingly, the direction

of these effects was opposite for the two haplogroups. Specifically, the ε4A haplogroup was

associated with a decrease in APOE protein levels in ε4 carriers ($p = 0.004$, Fig. 7), while the

presence of the ε3B haplogroup showed the opposite effect, increasing APOE protein levels in

the CSF ($p = 0.025$), even after adjusting for the remaining covariates and *APOE* genotype. We

also examined the impact of the haplogroups on AD biomarkers (Supp. Fig. 5) and other proteins

located on 19q13 surrounding the *APOE* locus (Supp. Fig. 5), detecting negligible effects of the

ε4A and ε3B haplogroups on amyloid beta 42 levels, phospho-Tau81, NECTIN2, BCAM, and

APOC1.

Finally, by analyzing the phase of the ε3 and ε4 isoforms in combination with upstream variants

that configure the detected sub-haplotypes (Supp. Fig. 2), we concluded that the upstream variants

defining the ε4A haplogroup specifically reduce the levels of the APOE ε4 protein isoform in the

CSF. In contrast, the 3B haplogroup uniquely increases levels of the APOE ε3 isoform,

particularly in individuals with the ε3/ε4 genotype. This finding could be significant, as it suggests

that elevated ε4 allele expression may be detrimental (indicative of a toxic gain of function). Thus,

reducing ε4 expression in the brain could potentially benefit individuals experiencing

neurodegenerative processes.

4. Discussion

The *APOE* gene remains one of the most extensively studied genetic determinants of AD due to

its significant impact on AD risk. Despite decades of research since the initial identification of

the *APOE* ε4 allele as a major AD susceptibility factor[4,56], the precise molecular mechanisms by

which different *APOE* variants influence disease pathogenesis are still not fully understood.

Additionally, the extensive pleiotropy of the *APOE* locus, which modulates the levels of

numerous proteins in plasma and CSF, several cardiovascular traits, and various

neurodegenerative diseases, remains a question that continues to fascinate the scientific

community.

Regarding the potential mechanism of action of *APOE* in relation with Alzheimer's disease, the

controversy continues. While the ADGC consortium has recently reviewed the substantial

evidence suggesting that the ε4 allele may act as a toxic gain-of-function variant[57], consensus is

still lacking on whether its effects result from a toxic gain or a loss of function. In fact, a large

study conducted within the Copenhagen Heart Study cohort suggested that reducing APOE

protein expression in plasma, regardless of the protein isoform, could have detrimental effects,

thereby supporting the notion of a potential loss-of-function mechanism for the APOE protein[58,59].

This alternative mechanism has been further supported by classic studies using *APOE* knockout

(KO) mouse models, which demonstrated similar effects on cardiovascular traits, particularly

arteriosclerosis[60,61]. Additionally, the loss-of-function mechanisms that explain the deleterious

effect of the *APOE* ε4 allele are further supported by its demonstrated partial inability to transport

lipoproteins effectively. Specifically, the ε4 isoform has reduced capacity to clear chylomicrons,

VLDL particles, and other triglyceride-rich particles from the bloodstream, leading to

dyslipidemia and associated cardiovascular outcomes, including atherosclerosis or

hypertension[62,63]. However, while these robust demonstrations of the *APOE* ε4 isoform's

hypomorphism (i.e., partial loss-of-function) role are linked to cardiovascular traits, they are

considered independent of its effect on increasing dementia risk in humans[64].

Connecting these controversies with our findings, it is tempting to speculate that, depending on

sub-haplotype configurations and the effects of variants influencing *APOE* expression across

different tissues, we might explain the paradoxical toxic gain-of-function effects of the same

alleles on central nervous system physiology, alongside hypomorphic loss-of-function effects in

the periphery and vascular system for the same protein isoforms. However, large-scale population

studies examining central and peripheral APOE levels, as well as molecular experiments to assign

tissue specificity to the array of regulatory elements controlling *APOE* gene expression, are

essential. Much more research is needed to understand the precise regulation of *APOE* gene

expression in cells influencing both atherosclerosis and Alzheimer's disease risk[65].

The existence of cis-acting modulators increasing or decreasing the inherent risk associated to

APOE ε4 isoform is largely suspected and a few studies have been conducted to uncover the

potential modulators surrounding the *APOE* locus[66–69]. Importantly, there are evidences in the

literature suggesting a differential risk of the *APOE* isoforms in different human ancestries. For

example, different research work identified genetic markers upstream the *APOE* locus that might

explain the attenuated or increase effect of the *APOE* ε4 in an ancestry-dependent manner[6,8–10].

Connected with this idea, there are previous descriptions of common variants surrounding the

APOE locus that might alter the transcription of the mRNA[70,71]. Some of the common variants

we have detected during our sequencing study such rs40550977 or rs440446[72,73] among others

have been proposed as candidate factors modulating *APOE* expression with different levels of

evidence. In addition, the 3' region of the gene including the exon 4 (which encode the *APOE*

isoforms itself) have been proven to contain an epigenetic modulator acting as CpG element[74–77].

Additionally, regional and GWAS analyses of plasma APOE protein levels also support the notion

that a relatively large number of independent variants surrounding the locus might alter the

production of the *APOE* isoform even in a tissue specific manner[69,78].

Previous research reinforces the importance of phasing the potential modulators of *APOE*

expression with APOE protein isoforms because a differential distribution of different

haplogroups among populations might contribute to explain differences in the effect of the *APOE*

risk alleles in different genetic backgrounds. The use of ONT for generating long-range

haplotypes has proven instrumental in studying the *APOE* locus[22] and other regions across the

human genome[79], although the existence of technical problems must not be ignored[80]. However,

due to the small scale of previously reported studies, little is known about the clinical impact of

the detected sub-haplotypes or common haplogroups. To our knowledge, this is the largest study

indicating differential effects of sub haplotypes within the ε4 and ε3 isoforms. Our strategy has

permitted the accurate phasing of the nearest 5' (upstream) intragenic regulatory variants in the

locus with the classic protein isoforms, resolving the homoplasy of key variants upstream the

exon 4 of the gene. This enabled us to identify distinct sub-haplotypes for the common *APOE* ε3

and ε4 isoforms in the Spanish population, providing for the first time insights into how these

haplotypic configurations might modulate disease progression in MCI subjects and influence

APOE protein expression in the CSF.

Importantly, the haplotypic architecture identified using our method is somewhat consistent with

other small-scale studies previously published. *Fullerton et al.* used allele-specific amplification

techniques twenty-four years ago to resolve homoplasy variants in the *APOE* locus and detected

ε3 and ε4 sub haplotypes across diverse populations[21]. Our findings confirm these early

observations, particularly for the common haplogroups detected. More recently, *Abondio et al.*

demonstrated the presence of ε3 and ε4 sub haplotypes across geographic macro areas[81]. Although

their study used inference methods rather than long-read sequencing, the six core variants they

identified (rs440446, rs565782572, rs769449, rs769450, rs429358, and rs7412) represent a shared

haplotype cluster that aligns well with our findings. This study reinforces the relevance of long-

read sequencing for characterizing *APOE* haplogroups and validating the core haplotype

composition in different human populations. The study of intragenic haplogroups may be

particularly relevant because they are not dependent on ancestry background. This implies that

detected haplogroups are present across different ancestries, albeit in varying proportions.

Furthermore, the combination of these intragenic haplogroups with other distal and more

ancestry-dependent elements could complicate the interpretation of studies aimed at identifying

ancestry-specific modulators of the ε4 allele. In any case, large scale studies are necessary to

elucidate the intragenic haplogroup composition in different populations and its impact in ε4

expressivity.

From an evolutionary perspective, the distinct regulatory profiles detected for ε4A and ε3B

haplogroups raise intriguing questions about the evolutionary trajectory of the human *APOE* gene.

Previous studies have suggested that the ε4 allele may have been positively selected in ancestral

human populations due to its advantageous effects on lipid metabolism and immune response[62].

However, the emergence of sub haplotypes such as ε4A, which appears to mitigate some of the

adverse effects of the ε4 allele, suggests a more complex evolutionary history involving balancing

selection and regulatory adaptations.

The opposing effects of the ε4A and ε3B haplogroups on CSF APOE protein levels are

noteworthy. The ε4A haplogroup, associated with a significant reduction in APOE ε4 isoform

levels, suggests a potential attenuation of the well-established toxic gain-of-function model

proposed for the ε4 allele[57]. Previous research has shown that the ε4 allele exacerbates amyloid

pathology and tau hyper-phosphorylation, thereby contributing to neurodegeneration through

both direct and indirect mechanisms[18]. However, our findings indicate that specific functional

variants within the ε4A haplogroup might counteract this effect by reducing the levels of the toxic

ε4 isoform, potentially mitigating its deleterious impact in ε4 carriers.

Conversely, the ε3B haplogroup was associated with an increase in APOE ε3 protein levels,

particularly in individuals carrying the ε3/ε4 genotype. This suggests that certain variants within

this haplogroup may act elevating ε3 isoform expression and potentially compensating for the

presence of the ε4 allele. These isoform-specific regulatory effects highlight the complex

interplay between promoter variants and overall *APOE* function, underscoring the need to

consider haplotype configurations in future genetic studies.

Our study suggests that the combination of intragenic regulatory variants may fine-tune *APOE*

expression. This is supported by our observation that the ε4A and ε3B haplogroups exert opposing

effects despite sharing a common genetic background, including the T-allele of the homoplasic

rs405509 with the ε4 and ε3 alleles, respectively. However, each is uniquely combined with

different SNPs in intronic enhancers of the gene (the C-allele of rs440646 in haplotype 2 and its

derivatives [ε3B haplogroup] and the A-allele of rs769449 in the ε4A haplogroup). It is possible

that the specific combination of these variants within enhancer-active regions may induce

paradoxical effects on the gene expression of homoplasic variants. However, an exhaustive

functional characterization of the entire intragenic haplotypes is necessary to understand the

mechanisms associated with our findings.

Present results may have significant implications for the design of *APOE*-targeted gene therapies.

Gene-editing strategies aimed at controlling ε4 expression, such as CRISPR-Cas9 or epigenome-

based approaches[82], should carefully consider the potential for unintended effects on neighboring

regulatory elements within the less harmful ε4A haplogroup. Likewise, therapeutic strategies that

seek to upregulate ε3 expression must account for the presence of enhancers within the ε3B

haplogroup, which could amplify ε3 isoform levels. Again, a comprehensive understanding of

APOE haplotype structure is thus essential for the rational design of future isoform-specific

interventions.

Despite the novel insights provided by our study, several limitations must be acknowledged. First,

our sample size, while robust for a single-cohort study, may not capture the full spectrum of

haplotypes present across diverse populations. Ancestry-specific effects, highlighted in several

studies [11,83,84], also influence the impact of these *APOE* intragenic haplogroups on AD risk. Future

studies should aim to replicate our findings in larger, multi-ethnic cohorts to assess the

generalizability of these results. Second, measuring APOE protein levels in CSF remains

challenging, as different platforms yield varying results depending on the assay method used (e.g.,

SomaScan, ELISA, Olink). Therefore, while our findings are robust, they should be interpreted

with caution until validated using complementary methodologies. Third, our study focused

exclusively on APOE protein levels in the CSF. The effects of these intragenic haplogroups in

other tissues, particularly circulating APOE measured in plasma and produced in the liver, remain

to be determined. A more comprehensive analysis of the impact of these intragenic haplogroups

across multiple cell types and tissues is warranted. Fourth, this study centers on the *APOE* gene

itself without accounting for the broader *APOE* region, which includes other potentially AD-

related genes such as *TOMM40*, *BCAM*, or *APOC1*. These neighboring loci are known to interact

with *APOE* at the regulatory level. Future research should aim to map the full haplotype structure

of the entire 19q13 region to provide a more complete understanding of its functional and genetic

landscape. Fifth, due to the inherent limitations of ONT, we focused our sequencing effort solely

on SNV sites. Indel variants might also contribute to intragenic haplotype diversity of the *APOE*

locus. Further sequencing efforts combining short-read and long-read sequencing are necessary

to fully characterize the exact sequence composition of *APOE* intragenic haplogroups. This

information will be essential and relevant for elucidating the functional mechanisms behind the

observed effects on APOE protein isoform expressivity.

In summary, our high-resolution intragenic haplotype analysis of the *APOE* gene revealed

different alleles within the ε3 and ε4 backgrounds that have distinct effects on APOE protein

levels in the CSF and on MCI to AD progression. These findings provide new insights into the

functional regulation of *APOE* in AD, suggesting that precise modulation of isoform-specific

expression may be a promising therapeutic strategy. Further research is needed to explore the

broader implications of these haplogroups in AD risk and pathogenesis and to refine our

understanding of the regulatory mechanisms that govern *APOE* function in the brain. The

prevalence of specific haplotypes, alongside insights into their evolutionary trajectories and

possible Neanderthal genetic contributions, opens new research avenues aimed at elucidating the

genetic elements that influence the expression of *APOE* locus. Our findings lay the groundwork

for further exploration of the implications of intragenic *APOE* subhaplotypes in human

populations, emphasizing the importance of continued research in *APOE* regulation and its impact

in AD and other human conditions.

5. References

1. 2023 Alzheimer's disease facts and figures. *Alzheimer's & Dementia* **19**, 1598–1695

(2023).

2. 2024 Alzheimer's disease facts and figures. *Alzheimer's & Dementia* **20**, 3708–3821

(2024).

3. Rodríguez-Gómez, O., Palacio-Lacambra, M. E., Palasí, A., Ruiz-Laza, A. & Boada-

Rovira, M. Prevention of Alzheimer's Disease: A Global Challenge for Next Generation

Neuroscientists. *JAD* **42**, S515–S523 (2014).

4. Corder, E. H. *et al.* Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of

Alzheimer's Disease in Late Onset Families. *Science* **261**, 921–923 (1993).

5.   Moreno–Grau, S. *et al.* Exploring *APOE* genotype effects on Alzheimer's disease risk and

amyloid β burden in individuals with subjective cognitive decline: The FundacioACE

Healthy Brain Initiative (FACEHBI) study baseline results. *Alzheimer's & Dementia*

14, 634–643 (2018).

6.   Celis, K. *et al.* Ancestry-related differences in chromatin accessibility and gene expression

of *APOE* ε4 are associated with Alzheimer's disease risk. *Alzheimer's & Dementia* **19**,

3902–3915 (2023).

7.   Reitz, C., Pericak-Vance, M. A., Foroud, T. & Mayeux, R. A global view of the genetic

basis of Alzheimer disease. *Nat Rev Neurol* **19**, 261–277 (2023).

8.   Nuytemans, K. *et al.* Identifying differential regulatory control of *APOE* ε4 on African

versus European haplotypes as potential therapeutic targets. *Alzheimer's & Dementia*

18, 1930–1942 (2022).

9.   Rajabli, F. *et al.* A locus at 19q13.31 significantly reduces the ApoE ε4 risk for Alzheimer's

Disease in African Ancestry. *PLoS Genet* **18**, e1009977 (2022).

10. Griswold, A. J. *et al.* Increased *APOE* ε4 expression is associated with the difference in

Alzheimer's disease risk from diverse ancestral backgrounds. *Alzheimer's & Dementia*

17, 1179–1188 (2021).

11. Farrer, L. A. *et al.* Effects of age, sex, and ethnicity on the association between

apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer

Disease Meta Analysis Consortium. *JAMA* **278**, 1349–1356 (1997).

12. Bertholim-Nasciben, L. *et al.* African origin haplotype protective for Alzheimer's disease in

APOE ε4 carriers: exploring potential mechanisms. Preprint at

https://doi.org/10.1101/2024.10.24.619909 (2024).

13. Alzheimer's Disease Neuroimaging Initiative (ADNI)* *et al.* Multiomics integrative

analysis identifies APOE allele-specific blood biomarkers associated to Alzheimer's disease

etiopathogenesis. *Aging* **13**, 9277–9329 (2021).

14. Belloy, M. E., Napolioni, V. & Greicius, M. D. A Quarter Century of APOE and

Alzheimer's Disease: Progress to Date and the Path Forward. *Neuron* **101**, 820–838 (2019).

15. Holtzman, D. M., Herz, J. & Bu, G. Apolipoprotein E and Apolipoprotein E Receptors:

Normal Biology and Roles in Alzheimer Disease. *Cold Spring Harbor Perspectives in*

Medicine **2**, a006312–a006312 (2012).

16. Lynch, J. R., Morgan, D., Mance, J., Matthew, W. D. & Laskowitz, D. T. Apolipoprotein E

modulates glial activation and the endogenous central nervous system inflammatory

response. *Journal of Neuroimmunology* **114**, 107–113 (2001).

17. Butterfield, D. A. & Mattson, M. P. Apolipoprotein E and oxidative stress in brain with

relevance to Alzheimer's disease. *Neurobiology of Disease* **138**, 104795 (2020).

18. Liu, C.-C., Liu, C.-C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer

disease: risk, mechanisms and therapy. *Nat Rev Neurol* **9**, 106–118 (2013).

19. Clarke, J. *et al.* Continuous base identification for single-molecule nanopore DNA

sequencing. *Nature Nanotech* **4**, 265–270 (2009).

20. Van Dijk, E. L., Jaszczyszyn, Y., Naquin, D. & Thermes, C. The Third Revolution in

Sequencing Technology. *Trends in Genetics* **34**, 666–681 (2018).

21. Fullerton, S. M. *et al.* Apolipoprotein E Variation at the Sequence Haplotype Level:

Implications for the Origin and Maintenance of a Major Human Polymorphism. *The*

American Journal of Human Genetics **67**, 881–900 (2000).

22. Maestri, S. *et al.* A Long-Read Sequencing Approach for Direct Haplotype Phasing in

Clinical Settings. *IJMS* **21**, 9177 (2020).

23. Boada, M. *et al.* Design of a comprehensive Alzheimer's disease clinic and research center

in Spain to meet critical patient and family needs. *Alzheimer's and Dementia* (2014)

doi:10.1016/j.jalz.2013.03.006.

24. Petersen, R. C. Mild cognitive impairment as a diagnostic entity. in *Journal of Internal*

Medicine (2004). doi:10.1111/j.1365-2796.2004.01388.x.

25. Petersen, R. C. *et al.* Mild cognitive impairment: Clinical characterization and outcome.

Archives of Neurology (1999) doi:10.1001/archneur.56.3.303.

26. Alegret, M. *et al.* Cut-off Scores of a Brief Neuropsychological Battery (NBACE) for

Spanish Individual Adults Older than 44 Years Old. *PLoS ONE* **8**, e76436 (2013).

27. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*.

(American Psychiatric Association, 2013). doi:10.1176/appi.books.9780890425596.

28. McKhann, G. M. *et al.* The diagnosis of dementia due to Alzheimer's disease:

Recommendations from the National Institute on Aging-Alzheimer's Association

workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's and Dementia*

(2011) doi:10.1016/j.jalz.2011.03.005.

29. Román, G. C. *et al.* Vascular dementia: Diagnostic criteria for research studies: Report of

the ninds-airen international workshop*. *Neurology* (1993) doi:10.1212/wnl.43.2.250.

30. Mesulam, M.-M., Grossman, M., Hillis, A., Kertesz, A. & Weintraub, S. The core and halo

of primary progressive aphasia and semantic dementia. *Ann Neurol.* **54**, S11–S14 (2003).

31. McKeith, I. G. *et al.* Diagnosis and management of dementia with Lewy bodies: Fourth

consensus report of the DLB Consortium. *Neurology* **89**, 88–100 (2017).

32. Vanderstichele, H. *et al.* Standardization of preanalytical aspects of cerebrospinal fluid

biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the

Alzheimer's Biomarkers Standardization Initiative. *Alzheimer's & Dementia* **8**, 65–73

(2012).

33. Blennow, K. & Zetterberg, H. The Application of Cerebrospinal Fluid Biomarkers in Early

Diagnosis of Alzheimer Disease. *Medical Clinics of North America* **97**, 369–376 (2013).

34. Orellana, A. *et al.* Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers

for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. *IJMS* **23**, 6891

(2022).

35. Brosseron, F. *et al.* Soluble TAM receptors sAXL and sTyro3 predict structural and

functional protection in Alzheimer's disease. *Neuron* **110**, 1009-1022.e4 (2022).

36. Martino Adami, P. V. *et al.* Matrix metalloproteinase 10 is linked to the risk of progression

to dementia of the Alzheimer's type. *Brain* **145**, 2507–2517 (2022).

37. Moreno-Grau, S. *et al.* Genome-wide association analysis of dementia and its clinical

endophenotypes reveal novel loci associated with Alzheimer's disease and three causality

networks: The GR@ACE project. *Alzheimer's & Dementia* **15**, 1333–1347 (2019).

800 38. Rojas, I. de *et al.* Common variants in Alzheimer's disease and risk stratification by

801   polygenic risk scores. *Nature Communications* **12**, 3417 (2021).

802 39. García-González, P. *et al.* A Novel Susceptibility Locus in *NFASC* Highlights

803   Oligodendrocytes and Myelination in Progressive Supranuclear Palsy Pathology. Preprint at

804   https://doi.org/10.1101/2024.06.21.24309279 (2024).

805 40. Leija-Salazar, M. *et al.* Evaluation of the detection of *GBA* missense mutations and other

806   variants using the Oxford Nanopore MinION. *Molec Gen & Gen Med* **7**, e564 (2019).

807 41. Martin, M. *et al.* WhatsHap: fast and accurate read-based phasing. Preprint at

808   https://doi.org/10.1101/085050 (2016).

809 42. Patterson, M. *et al.* W HATS H AP : Weighted Haplotype Assembly for Future-Generation

810   Sequencing Reads. *Journal of Computational Biology* **22**, 498–509 (2015).

811 43. Tamura, K., Stecher, G. & Kumar, S. MEGA11: Molecular Evolutionary Genetics Analysis

812   Version 11. *Molecular Biology and Evolution* **38**, 3022–3027 (2021).

813 44. Estimation of the number of nucleotide substitutions in the control region of mitochondrial

814   DNA in humans and chimpanzees. *Molecular Biology and Evolution* (1993)

815   doi:10.1093/oxfordjournals.molbev.a040023.

816 45. Harrison, P. W. *et al.* Ensembl 2024. *Nucleic Acids Research* **52**, D891–D899 (2024).

817 46. Morató, X. *et al.* Associations of plasma SMOC1 and soluble IL6RA levels with the

818   progression from mild cognitive impairment to dementia. *Brain, Behavior, & Immunity -*

819   *Health* **42**, 100899 (2024).

820 47. Darian, J. C., Kundu, R., Rajaby, R. & Sung, W.-K. Constructing telomere-to-telomere

821   diploid genome by polishing haploid nanopore-based assembly. *Nat Methods* **21**, 574–583

822   (2024).

823 48. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed

824   Program. *Nature* **590**, 290–299 (2021).

825 49. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 122 (2016).

826 50. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human

827   genetic variants. *Nat Genet* **46**, 310–315 (2014).

51. Arboleda-Velasquez, J. F. *et al.* Resistance to autosomal dominant Alzheimer's disease in

an APOE3 Christchurch homozygote: a case report. *Nat Med* **25**, 1680–1683 (2019).

52. Hernandez, I. *et al.* Heterozygous *APOE* Christchurch in familial Alzheimer's disease

without mutations in other Mendelian genes. *Neuropathology Appl Neurobio* **47**, 579–582

(2021).

53. Haidar, M., Schmid, B., Ruiz, A., Ebneth, A. & Cabrera-Socorro, A. Generation of three

isogenic, gene-edited iPSC lines carrying the APOE-Christchurch mutation into the three

common APOE variants: APOE2Ch, APOE3Ch and APOE4Ch. *Stem Cell Research* **77**,

103414 (2024).

54. Puerta, R. *et al.* Head-to-Head Comparison of Aptamer- and Antibody-Based Proteomic

Platforms in Human Cerebrospinal Fluid Samples from a Real-World Memory Clinic

Cohort. *IJMS* **26**, 286 (2024).

55. Cruchaga, C. *et al.* Cerebrospinal fluid APOE levels: an endophenotype for genetic studies

for Alzheimer's disease. *Human Molecular Genetics* **21**, 4558–4571 (2012).

56. Corder, E. H. *et al.* Protective effect of apolipoprotein E type 2 allele for late onset

Alzheimer disease. *Nat Genet* **7**, 180–184 (1994).

57. Vance, J. M. *et al.* Report of the APOE4 National Institute on Aging/Alzheimer Disease

Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a

Therapeutic Goal for Alzheimer's Disease. *Annals of Neurology* **95**, 625–634 (2024).

58. Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G. & Frikke-Schmidt, R. *APOE*

and dementia – resequencing and genotyping in 105,597 individuals. *Alzheimer's &*

Dementia **16**, 1624–1637 (2020).

59. Rasmussen, K. L., Luo, J., Nordestgaard, B. G., Tybjærg-Hansen, A. & Frikke-Schmidt, R.

APOE and vascular disease: Sequencing and genotyping in general population cohorts.

Atherosclerosis **385**, 117218 (2023).

60. Plump, A. S. *et al.* Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-

deficient mice created by homologous recombination in ES cells. *Cell* **71**, 343–353 (1992).

61. Zhang, S. H., Reddick, R. L., Piedrahita, J. A. & Maeda, N. Spontaneous

Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E. *Science* **258**,

468–471 (1992).

62. Mahley, R. W. & Rall, S. C. Apolipoprotein E: Far More Than a Lipid Transport Protein.

Annu. Rev. Genom. Hum. Genet. **1**, 507–537 (2000).

63. Gregg, R. E. *et al.* Abnormal in vivo metabolism of apolipoprotein E4 in humans. *J. Clin.*

Invest. **78**, 815–821 (1986).

64. Prince, M. *et al.* The association between *APOE and dementia does not seem to be*

mediated by vascular factors. *Neurology* **54**, 397–397 (2000).

65. Van Den Kommer, T. N. *et al.* The role of extracerebral cholesterol homeostasis and ApoE

e4 in cognitive decline. *Neurobiology of Aging* **33**, 622.e17-622.e28 (2012).

66. Ramos, M. C. *et al.* Neuronal specific regulatory elements in apolipoprotein E gene

proximal promoter: *NeuroReport* **16**, 1027–1030 (2005).

67. Artiga, M. J. *et al.* Risk for Alzheimer's disease correlates with transcriptional activity of

the APOE gene. *Human Molecular Genetics* **7**, 1887–1892 (1998).

68. Town, T. *et al.* The −491A/T apolipoprotein E promoter polymorphism association with

Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE

polymorphism. *Neuroscience Letters* **252**, 95–98 (1998).

69. Chen, Q. *et al.* Identification of a specific APOE transcript and functional elements

associated with Alzheimer's disease. *Mol Neurodegeneration* **19**, 63 (2024).

70. Lambert, J. C. *et al.* Contribution of *APOE* promoter polymorphisms to Alzheimer's

disease risk. *Neurology* **59**, 59–66 (2002).

71. Bullido, M. J. *et al.* A polymorphism in the regulatory region of APOE associated with risk

for Alzheimer's dementia. *Nat Genet* **18**, 69–71 (1998).

72. Rantalainen, V. *et al.* APOE ε4, rs405509, and rs440446 promoter and intron-1

polymorphisms and dementia risk in a cohort of elderly Finns—Helsinki Birth Cohort

Study. *Neurobiology of Aging* **73**, 230.e5-230.e8 (2019).

73. Prada, D. *et al.* Influence of multiple APOE genetic variants on cognitive function in a

cohort of older men – results from the Normative Aging Study. *BMC Psychiatry* **14**, 223

(2014).

74. Wang, S.-C., Oelze, B. & Schumacher, A. Age-Specific Epigenetic Drift in Late-Onset

Alzheimer's Disease. *PLoS ONE* **3**, e2698 (2008).

75. Foraker, J. *et al.* The APOE Gene is Differentially Methylated in Alzheimer's Disease. *JAD*

48, 745–755 (2015).

76. Lee, E.-G. *et al.* Redefining transcriptional regulation of the APOE gene and its association

with Alzheimer's disease. *PLoS ONE* **15**, e0227667 (2020).

77. Mancera-Páez, O. *et al.* Differential Methylation in APOE (Chr19; Exon Four; from

44,909,188 to 44,909,373/hg38) and Increased Apolipoprotein E Plasma Levels in Subjects

with Mild Cognitive Impairment. *IJMS* **20**, 1394 (2019).

78. Aslam, M. M. *et al.* Genome-wide analysis identifies novel loci influencing plasma

apolipoprotein E concentration and Alzheimer's disease risk. *Mol Psychiatry* **28**, 4451–

4462 (2023).

79. Bowden, R. *et al.* Sequencing of human genomes with nanopore technology. *Nat Commun*

10, 1869 (2019).

80. Laver, T. W. *et al.* Pitfalls of haplotype phasing from amplicon-based long-read

sequencing. *Sci Rep* **6**, 21746 (2016).

81. Abondio, P., Bruno, F. & Luiselli, D. Apolipoprotein E (APOE) Haplotypes in Healthy

Subjects from Worldwide Macroareas: A Population Genetics Perspective for

Cardiovascular Disease, Neurodegeneration, and Dementia. *CIMB* **45**, 2817–2831 (2023).

82. Kantor, B., Rittiner, J., Nicholls, P. J. & Chiba-Falek, O. *APOE* -targeted epigenome

therapy for late onset Alzheimer's disease. *Alzheimer's & Dementia* **18**, e060974 (2022).

83. Mahley, R. W. & Huang, Y. Apolipoprotein E Sets the Stage: Response to Injury Triggers

Neuropathology. *Neuron* **76**, 871–885 (2012).

84. Belloy, M. E. *et al.* APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and

Population Ancestry. *JAMA Neurol* **80**, 1284 (2023).

85. Schwarz, J. M., Rödelsperger, C., Schuelke, M. & Seelow, D. MutationTaster evaluates

disease-causing potential of sequence alterations. *Nat Methods* **7**, 575–576 (2010).

6. Funding & Acknowledgments

The present work has been performed as part of the Doctoral thesis of Pablo García-González at the University of Barcelona (Barcelona, Spain). We would like to thank patients and controls who participated in this project. They were processed following standard operating procedures with the appropriate approval of the Ethical and Scientific Committee. Authors acknowledge the support of the Agency for Innovation and Entrepreneurship (VLAIO) grant Nº PR067/21 and Janssen for the HARPONE project and the ADAPTED project the EU/EFPIA Innovative Medicines Initiative Joint Undertaking Grant Nº 115975. Also, the Spanish Ministry of Science and Innovation, Proyectos de Generación de Conocimiento grants PID2021-122473OA-I00, PID2021-123462OB-I00 and PID2019-106625RB-I00. ISCIII, Acción Estratégica en Salud integrated in the Spanish National R+D+I Plan and financed by ISCIII Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER "Una manera de hacer Europa") grants PI17/01474, PI19/00335, PI22/01403 and PI22/00258. The support of CIBERNED (ISCIII) under the grants CB06/05/2004 and CB18/05/00010. The support from PREADAPT project, Joint Program for Neurodegenerative Diseases (JPND) grant Nº AC19/00097, and from DESCARTES project, German Research Foundation (DFG). The support of Fundación bancaria "La Caixa", Fundación ADEY, Fundación Echevarne and Grifols SA (GR@ACE project). ACF received support from the Instituto de Salud Carlos III (ISCIII) under the grant Sara Borrell (CD22/00125). PGG was supported by CIBERNED employment plan (CNV-304-PRF-866). IdR is supported by the ISCIII 706 under the grant FI20/00215. AR is also supported by STAR Award. University of Texas System. Tx, United States, The South Texas ADRC. National Institute of Aging. National Institutes of Heath. USA. (P30AG066546), the Keith M. Orme and Pat Vigeon Orme Endowed Chair in Alzheimer's and Neurodegenerative Diseases (2024-2025) and Patricia Ruth Frederick Distinguished Chair for Precision Therapeutics in Alzheimer's and Neurodegenerative Diseases (2025-2028). Part of this study was also funded

937   by the German Federal Ministry of Education and Research (BMBF) within the EU program

938   JPND (Grant number: PreADAPT project 01ED2007A) and by BMBF (Grant numbers:

939   DESCARTES project 01EK2102B and 01EK2102A).

7. Figures

Figure 1: Summary of Variant Class, Substitution Types, Genomic Location, and Annotation Confidence for *APOE* Gene Variants.

Figure 2: Comparison of common variant frequencies Across ONT Results, GR@ACE samples and the TOPMed database. The GR@ACE data reflects the frequencies in 1026 overlapping individuals genotyped using the Affymetrix Axiom Spain Biobank array and imputed with the TOPMed reference panel, as described elsewhere [37–39]. TOPMed frequencies reflect those reported by dbSNP build 151.

Figure 3: Comparison of Mutation Taster Predictions and CADD Scores for Observed *APOE* **Coding Variants.** Panel A illustrates the distribution of Mutation Taster[85] predictions for the coding variants observed in the gene. Variants are categorized into four groups: Disease Causing (Predicted), Disease Causing (based on Literature records), Polymorphism (Benign), and Unclassified. panel B presents the CADD scores for each observed variant in the *APOE* gene (most of them are very low). The scores are plotted alongside their corresponding consequence annotations predicted by VEP, such as missense variant, synonymous variant, or missense with potential splice region consequence.

Figure 4: *APOE* Haplotype Analysis in a Spanish Population. The figure illustrates the distribution and characteristics of the *APOE* haplotypes identified in a Spanish population. Panel A shows the top 17 haplotypes with a count greater than two, detailing their specific sequences, frequencies, and classifications based on ε2/ε3/ε4 isoform information. Panel B provides a graphical representation of the haplotype distribution, illustrating both the count of individuals carrying each haplotype (bars) and the accumulated frequency of these haplotypes in the population (line). Haplotype backgrounds are color-coded: red indicates ε4, orange indicates ε3, and green indicates ε2. Panel C provides the distribution of haplotype counts across different haplogroups using log-scaled visualization. Numbers at the tip of each bar indicate the count of individuals for each haplotype.

Figure 5: Phylogenetic Network of *APOE* intragenic Haplotypes Based on SNV Variations in the Spanish Population. This phylogenetic network illustrates the evolutionary relationships among the 59 *APOE* haplotypes identified in the Spanish population. Each node represents a distinct haplotype, and branches reflect the genetic distances based on single nucleotide variant (SNV) differences. The shapes and colors of the nodes correspond to specific isoform backgrounds: Orange triangles: ε3 background. Green triangle: Christchurch mutation under the isoform ε3 background. Green diamond: Haplogroup 2 (ε2 background). Red squares: ε4 background). Blue diamond is the ancestral allele sequence according to EMBL database. The

clustering of nodes indicates shared evolutionary paths, highlighting how specific haplotypes are grouped based on shared genetic variations.

Figure 6: Distribution and Protective Effects of *APOE* Haplogroups (4A and 3B) on Disease Progression Analyzed Using Cox Proportional Hazard Models. Panel A: Pie chart showing the distribution of subjects based on the presence of 4A, 3B, both haplogroups (3B/4A), or neither (None). Panel B: Cox proportional hazard model displaying adjusted hazard ratios for the presence of 4A and 3B haplogroups along with other covariates (*APOE* genotype, demographics, and AD biomarkers). Panel C: Survival analysis highlighting the protective effect of the 4A haplogroup (HR = 0.599, p = 0.002). Panel D: Survival analysis showing the protective impact of the 3B haplogroup (HR = 0.79, p = 0.037).

Figure 7: Effect of *APOE* Genotype and Haplogroups on CSF APOE Protein Levels Using Olink Measurements. This figure illustrates the impact of *APOE* genotype and the presence of ε4A and ε3B haplogroups on APOE protein levels in CSF measured using the Olink platform. Panel A: Boxplots showing CSF APOE protein levels across *APOE* genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4, and ε4/ε4). The observed decreasing trend in APOE protein levels by genotype (ε2 > ε3 > ε4) replicates previous findings by other groups, confirming the reliability of the Olink measurements. Panel B: Partial eta-squared values indicating the effect of demographic and molecular covariates on CSF APOE levels measured using different platforms (Somascan APOE4, APOE3, and APOE2[54]; ELISA method[35]; and Olink[36]). The Olink platform explains the highest variance, supporting its use for accurate quantification of APOE protein levels. Panel C: Estimated marginal means of APOE protein levels by presence or absence of the ε4A haplogroup across different genotypes (ε2 carriers, ε3/ε3, and ε4 carriers). The ε4A haplogroup is associated with a significant decrease in APOE levels in ε4 carriers (p = 0.004), indicating a specific regulatory effect on the ε4 isoform. Panel D: Estimated marginal means of APOE protein levels by presence or absence of the ε3B haplogroup across different genotypes. The presence of the ε3B haplogroup is associated with increased APOE protein levels in CSF (p = 0.025), particularly in ε3/ε4 carriers, suggesting a specific upregulation of the ε3 isoform.

8. Tables

Table 1: Demographic, clinical, neurological, and biomarker Profiles of the ACE CSF Cohort

Demographics. N=1267	
Female (n, %)	733 (57.9%)
Age (years, sd)	72.68 (8.46)
BMI (kg/m3, sd)	26.9 (4.36)
Education (years, sd)	8.17 (4.77)
Syndromic diagnosis N(%)	
SCD (CDR=0)	79 (7.2%)
MCI (CDR=0.5)	795 (62.7%)
Dementia (CDR≥1)	381 (30.1%)
NA	12 (0.9%)
AT(N) classification N(%)	
A-T-N-	376 (29.7%)
A-T-N+	13 (1.0%)
A-T+N-	39 (3.1%)
A-T+N+	162 (12.8%)
A+T-N-	183 (14.4%)
A+T-N+	10 (0.8%)
A+T+N-	65 (5.1%)
A+T+N+	418 (33.0%)
NA	1 (0.1%)
APOE status (N,%)	
e2e2	4 (0.3%)
e2e3	91 (7.2%)
e2e4	24 (1.9%)
e3e3	734 (57.9%)
e3e4	354 (27.9%)
e4e4	60 (4.7%)
Other Clinical and Biochemical Data	
MMSE (mean, sd)	24.4 (4.41)
MCI converted/non conv (%)	354/366 (49.1%)
APOE CSF levels (n=499)(mean, sd)	6.02 (0.58)
pTau181 CSF levels	72.28 (45.35)
Amyloid b42 CSF levels	811.2 (393.5)
Total tau CSF Levels	469.2 (330.1)

rsid	CHR	POS	REF	ALT	CLASS	AF	AF TOPMed	AF GR@ACE	APOE region	Substitution type	Confidence	Qual/TotalReads
rs405509	19	44905579	T	G	COMMON	0,517954723	0,57121241	0,51712963	5'UTR	Transversion	Very good	8,80
19:44905709:G:A	19	44905709	G	A	NOVEL	0,00039	0	0	5'UTR	Transition	Caution	1,91
rs9282609	19	44905856	C	T	RARE	0,00078064	0,00739042	0,000459559	INTRON1	Transition	Very good	4,82
rs440446	19	44905910	C	G	COMMON	0,651834504	0,68091393	0,65437788	EXON1	Transversion	Very good	7,29
rs563571689	19	44905923	G	A	VERY_RARE	0,00078064	0,00064507	0,000377929	EXON1	Transition	Good	5,91
rs877973	19	44906026	C	A	COMMON	0,00039032	0,01068744	0,000459559	INTRON1	Transversion	Very good	4,33
rs528229851	19	44906085	G	C	VERY_RARE	0,00117096	*NA*	0,000755858	INTRON1	Transversion	Good	3,85
19:44906188:G:A	19	44906188	G	A	NOVEL	0,00039	0	0	INTRON1	Transition	Caution	3,56
rs769448	19	44906322	C	T	COMMON	0,007806401	0,01403224	0,007359706	INTRON1	Transition	Very good	2,70
rs147236548	19	44906338	G	T	VERY_RARE	0,00039032	0,004881817	0	INTRON1	Transversion	Caution	5,23
rs568489254	19	44906449	T	C	VERY_RARE	0,00078064	0,00057339	0	INTRON1	Transition	Good	2,46
19:44906536:T:C	19	44906536	T	C	NOVEL	0,00039	0	0	INTRON1	Transition	Caution	2,60
rs143063029	19	44906731	C	T	RARE	0,00234192	0,00148127	0,002757353	INTRON2	Transition	Very good	3,05
rs769449	19	44906745	G	A	COMMON	0,133099141	0,0772012	0,135272392	INTRON2	Transition	Very good	4,03
rs1370426995	19	44906802	G	C	VERY_RARE	0,00039032	3,98E-05	0	INTRON2	Transversion	Good	5,04
rs1488788938	19	44906941	C	T	VERY_RARE	0,00039032	*NA*	0	INTRON2	Transition	Good	2,38
rs769450	19	44907187	G	A	COMMON	0,392661983	0,3771343	0,398344066	INTRON2	Transition	Very good	5,87
19:44907281:T:A	19	44907281	T	A	NOVEL	0,00039	0	0	INTRON2	Transversion	Caution	4,98
rs1383989611	19	44907326	G	T	VERY_RARE	0,00078064	3,19E-05	0,000377644	INTRON2	Transversion	Good	4,36
19:44907563:C:G	19	44907563	C	G	NOVEL	0,00039	0	0	INTRON2	Transversion	Caution	9,30
rs1307012197	19	44907629	G	A	VERY_RARE	0,00039032	1,59E-05	0	INTRON2	Transition	Good	4,17
rs769451	19	44907654	T	G	RARE	0,009758002	0,00535965	0,009199632	INTRON2	Transversion	Very good	6,37

rs780533924	19	44907715	C	G	VERY_RARE	0,00039032	7,96E-06	0	INTRON2	Transversion	Good	4,63
rs111833428	19	44907785	G	A	VERY_RARE	0,00078064	0,00025484	0	EXON3	Transition	Good	1,75
rs1212454788	19	44907814	G	A	VERY_RARE	0,00039032	1,59E-05	0	EXON3	Transition	Good	2,37
rs769452	19	44907853	T	C	RARE	0,00273224	0,00134588	0,001382488	EXON3	Transition	Very good	2,79
19:44907977:G:C	19	44907977	G	C	NOVEL	0,00039	0	0	INTRON3	Transversion	Caution	5,58
rs560770492	19	44908033	C	T	VERY_RARE	0,00039032	9,56E-05	0,000377644	INTRON3	Transition	Good	4,76
rs746300299	19	44908048	G	A	VERY_RARE	0,00078064	*NA*	0	INTRON3	Transition	Good	3,32
rs952830931	19	44908176	G	A	VERY_RARE	0,00039032	3,98E-05	0	INTRON3	Transition	Good	2,07
rs865935864	19	44908380	C	T	VERY_RARE	0,00039032	1,59E-05	0	INTRON3	Transition	Good	3,35
rs1488164590	19	44908468	C	T	VERY_RARE	0,00039032	7,96E-06	0	INTRON3	Transition	Caution	0,20
rs1212541952	19	44908472	C	A	VERY_RARE	0,00039032	1,59E-05	0	INTRON3	Transversion	Good	3,72
19:44908477:C:T	19	44908477	C	T	NOVEL	0,00039	0	0	INTRON3	Transition	Caution	3,01
rs768998148	19	44908650	G	T	VERY_RARE	0,00039032	7,96E-06	0	EXON4	Transversion	Good	5,09
19:44908665:C:T	19	44908665	C	T	NOVEL	0,00039	0	0	EXON4	Transition	Caution	2,95
rs429358	19	44908684	T	C	COMMON	0,198672912	0,15559697	0,199355433	EXON4	Transition	Very good	2,50
rs121918393	19	44908756	C	A	VERY_RARE	0,00039032	7,96E-06	0	EXON4	Transversion	Good	4,27
rs954186991	19	44908762	G	A	VERY_RARE	0,00039032	7,96E-06	0	EXON4	Transition	Good	2,27
19:44908797:C:A	19	44908797	C	A	NOVEL	0,00039	0	0	EXON4	Transversion	Caution	5,22
rs7412	19	44908822	C	T	COMMON	0,047228728	0,08213876	0,044577206	EXON4	Transition	Very good	4,90
rs1434405741	19	44908837	C	G	VERY_RARE	0,00039032	7,96E-06	0	EXON4	Transversion	Good	3,64
rs72654468	19	44908947	C	T	VERY_RARE	0,00156128	0,00081231	0,000378788	EXON4	Transition	Good	1,72
rs530010303	19	44908999	C	T	VERY_RARE	0,00039032	5,57E-05	0	EXON4	Transition	Good	2,59
rs750138933	19	44909152	C	T	VERY_RARE	0,00039032	7,96E-06	0	EXON4	Transition	Good	3,15
rs749102800	19	44909209	G	A	VERY_RARE	0,00039032	3,19E-05	0,000377644	EXON4	Transition	Good	2,37
rs374329439	19	44909275	C	T	VERY_RARE	0,00078064	0,00045394	0,000755287	EXON4	Transition	Good	3,67
rs951089672	19	44909353	G	A	VERY_RARE	0,00039032	1,59E-05	0,000377644	EXON4	Transition	Good	3,47

Table 3. Complete list of the 17 Spanish *APOE* haplotypes with more than two occurrences in our population. Each row of the table corresponds to a distinct haplotype, specifying its sequence across the 48 positions within the APOE locus containing detected SNVs, along with its count, frequency and other classifications. The count column indicates the number of chromosomes carrying each specific haplotype. We also categorized the haplotypes into haplogroups, considering the common APOE isoform backgrounds (ε2, ε3, ε4) and the presence or absence of the alternative sequence (T-allele) of the homoplasic SNV rs405509 (Supp. Fig. 2), specifying the isoform background and the corresponding haplogroup for each haplotype. This classification framework aids in understanding the evolutionary relationships and potential health implications associated with each haplotype.

Haplotype	Sequence	Count	Frequency (%)	Background	Haplogroup
Haplotype1	GGCGGCGGCGTTCGGCATGCGTCGGTGCGGCCCCGCTCGCCCCCCGCG	970	38,069	ε3	3a
Haplotype2	TGCCGCGGCGTTCGGCGTGCGTCGGTGCGGCCCCGCTCGCCCCCCGCG	814	31,947	ε3	3b
Haplotype3	TGCGGCGGCGTTCAGCGTGCGTCGGTGCGGCCCCGCCCGCCCCCCGCG	310	12,166	ε4	4a
Haplotype4	GGCGGCGGCGTTCGGCGTGCGTCGGTGCGGCCCCGCCCGCCCCCCGCG	149	5,848	ε4	4b
Haplotype5	GGCGGCGGCGTTCGGCGTGCGTCGGTGCGGCCCCGCTCGCTCCCCGCG	120	4,710	ε2	2
Haplotype6	TGCCGCGGCGTTCGGCGTGCGGCGGTGCGGCCCCGCTCGCCCCCCGCG	22	0,863	ε3	3b
Haplotype7	TGCCGCGGTGTTCGGCGTGCGTCGGTGCGGCCCCGCTCGCCCCCCGCG	20	0,785	ε3	3b
Haplotype8	GGCGGCGGCGTTCGGCGTGCGTCGGTGCGGCCCCGCTCGCCCCCCGCG	19	0,746	ε3	3a
Haplotype9	TGCGGCGGCGTTCGGCGTGCGTCGGTGCGGCCCCGCCCGCCCCCCGCG	17	0,667	ε4	4a
Haplotype10	GGCGGCGGCGTTCAGCGTGCGTCGGTGCGGCCCCGCCCGCCCCCCGCG	16	0,628	ε4	4b
Haplotype11	TGCGGCGGCGTTCGGCGTGCGTCGGTGCGGCCCCGCTCGCCCCCCGCG	11	0,432	ε3	3b
Haplotype12	GGCCGCGGCGTTCGGCGTGCGTCGGTGCGGCCCCGCTCGCCCCCCGCG	8	0,314	ε3	3a
Haplotype13	TGCGGCGGCGTTCAGCGTGCGTCGGCGCGGCCCCGCCCGCCCCCCGCG	6	0,235	ε4	4a
Haplotype14	GGCGGCGGCGTTTGGCGTGCGTCGGTGCGGCCCCGCTCGCCCCCCGCG	6	0,235	ε3	3a
Haplotype15	TGCCGCGGCGTTCGGCGTGCGTCGGTGCGGCCCCGCTCGCCCTCCGCG	4	0,157	ε3	3b
Haplotype16	TGCGGCGGCGTTCGGCATGCGTCGGTGCGGCCCCGCTCGCCCCCCGCG	3	0,118	ε3	3b

| Haplotype17 | GGCGGCCGCGTTCGGCATGCGTCGGTGCGGCCCCGCTCGCCCCCCGCG | 3 | 0,118 | ε3 | 3a |

9. Supplementary Figures

Supplementary figure 1. PCR optimization. Different conditions tested in a single sample to search for optimal reaction. The optimal conditions were primer

pair APOE_III with 10% DMSO and buffer 2. The PCR products were examined by automated capillary electrophoresis using the LabChip GX Touch Nucleic

Acid Analyzer (Revvity, CLS138162) and the DNA 12K Reagent Kit (Revvity, 760569).

Supplementary Figure 2: **Phylogenetic and Genomic Analysis of the most common APOE Haplotypes in the Spanish Population.** This figure illustrates

the evolutionary relationships and genomic context of the top 15 most frequent *APOE* haplotypes identified in the Spanish population. The left panel shows a

phylogenetic network constructed using the Maximum Likelihood (ML) method, where haplotypes are grouped into distinct haplogroups based on their isoform

backgrounds (E3A, E3B, E4A, and E4B). Each haplotype is represented as a node, color-coded according to its classification, with orange nodes for E3

haplotypes, red for E4 haplotypes, and green for the epsilon 2 haplogroup. The ancestral haplotype, labelled as "Ancestral0" (blue diamond), serves as the root

from which other haplotypes diverged. The right panel provides a detailed map of the 4kb genomic region (chr19: 44,905,500-44,909,500) covering the *APOE*

gene, with annotations highlighting promoters, enhancers, CpG islands, and transcription factor binding sites that may impact gene regulation. A summary table

below the phylogenetic network details the SNV positions for each haplotype, observed count, and relative frequency in the population. This figure effectively

integrates phylogenetic analysis with functional genomic annotations, providing insights into the evolutionary diversification and regulatory landscape of *APOE*

haplotypes within the Spanish population.

Supplementary Figure 3: Distribution and Survival Analysis of APOE Haplogenotypes. Panel A shows a bar chart depicting the frequency distribution of

15 different *APOE* haplogenotypes, with the x-axis representing distinct haplogenotypes and the y-axis indicating their respective counts within the sample

population. The most common haplogenotypes are 3a/3b, 3a/3a, and 3b/3b. Panel B presents survival curves illustrating accumulated survival probabilities over

34 time for the 15 different *APOE* haplogenotypes, where each coloured line corresponds to a unique haplogenotype, demonstrating variation in survival across

35 different genetic profiles. Panels C-E display survival curves for specific subgroups of carriers: Panel C shows ε3/ε3 carriers divided by epsilon3 haplogroups

36 (3a/3a, 3a/3b, 3b/3b), Panel D shows ε3/ε4 carriers divided by epsilon3 and epsilon4 haplogroups (3a/3a, 3a/3b, 3b/3b), and Panel E shows e4e4 carriers divided

37 by epsilon4 haplogroups (4a/4a, 4a/4b, 4b/4b), revealing varying survival trends based on distinct haplogenotype groupings.

Supplementary Figure 4. Influence of haplogroups in AD biomarkers.

Supplementary Figure 5. Influence of haplogroups in other 19q13 genes (Olink platform).

Panel A: Mutation Taster

Panel B: CADD Score and Consequences

A

Distribution of Protective Haplogroups (4A, 3B, 3B/4A, None)

C

MCI to AD conversion Curves by the presence of the Epsilon 4A haplogroup

HR=0.599. p=0.002

D

MCI to AD conversion curves by the presence of the Epsilon 3B haplogroup

HR=0.79. p=0.037

B

Cox propotional Hazard risk Models adjusted by Age, sex, AD biomarkers in CSF and APOE genotypes

	B	SE	Wald	df	Sig.	H.R.	95,0% CI for H.R.	
							lower	upper
Age	,057	,009	43,746	1	,000	1,058	1,041	1,076
Sex	,004	,109	,002	1	,968	1,004	,812	1,242
Abeta_42_CSF	-,002	,000	68,733	1	,000	,998	,998	,999
P_tau181_CSF	,008	,001	52,964	1	,000	1,008	1,006	1,011
Presence_4a	-,512	,169	9,203	1	,002	,599	,431	,834
Presence_3b	-,236	,113	4,336	1	,037	,790	,633	,986
APOE gentoype	,228	,114	3,996	1	,046	1,256	1,004	1,571

A

B

C

D